pardon schreef op 3 januari 2019 13:11:
Bristol-Myers Squibb to acquire Celgene for $74B
Jan. 3, 2019 7:05 AM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor
In the first blockbuster merger of the new year, Bristol-Myers Squibb (NYSE:BMY) has agreed to acquire Celgene (NASDAQ:CELG) for $50/share in cash plus one BMY common share for each CELG share, valuing the transaction at $74B.
CELG shareholders will also receive one Contingent Value Right (CVR) for each share owned to receive a $9 cash payment triggered by the achievement of future regulatory milestones.
When the deal is closed, BMY shareholders will own ~69% of the combined company and CELG shareholders will own ~31%.
BMY will finance the transaction, expected to close in Q3, with cash on hand and debt. It will also accelerate its repurchase of up to $5B in common stock.